FDA Grants Approval for AREXVY, the First Respiratory Syncytial Virus (RSV) Vaccine
By: Urooj K. Malik, PharmD Candidate c/o 2024 On May 3, 2023, the United States (U.S.) Food and Drug Administration (FDA) approved Arexvy (RSVPreF3), the first vaccine to combat respiratory syncytial virus (RSV) for adults aged 60 and older.1 Overview of RSV RSV is a common respiratory virus that typically causes mild, cold-like symptoms that…